Another Underwhelming Quarterly Results Call

Quote

anonymous

Guest
Excuses, under estimations and extreme under performance of Inbrija

First Quarter 2022 Financial Results
For the quarter ended March 31, 2022, the Company reported INBRIJA net revenue of $3.7 million, compared to $5.0 million for the same quarter.

$15 M annual net sales years 3 of promotion . Lol

your lucky to hit peak sales lifetime of $25M
 










anonymous said:
Excuses, under estimations and extreme under performance of Inbrija

First Quarter 2022 Financial Results
For the quarter ended March 31, 2022, the Company reported INBRIJA net revenue of $3.7 million, compared to $5.0 million for the same quarter.

$15 M annual net sales years 3 of promotion . Lol

your lucky to hit peak sales lifetime of $25M
Click to expand...
Sales net revenues would be over $50mil in quarter if no Covid ! Blame the Covid for missing targets! Leadership is blameless !
 




QUOTE="Groomer Rump , post: 6682268"]Sales net revenues would be over $50mil in quarter if no Covid ! Blame the Covid for missing targets! Leadership is blameless ![/QUOTE]
 
















Acorda had $51m in cash, cash equivalents, short-term investments and restricted cash at the end of Q122, market cap for the company is ~$10m. I think this gives some sense for investors thinking on where the company is headed.
 




anonymous said:
Acorda had $51m in cash, cash equivalents, short-term investments and restricted cash at the end of Q122, market cap for the company is ~$10m. I think this gives some sense for investors thinking on where the company is headed.
Click to expand...

It’s never a good sign when the Tidy Bowl man shows up to your investor call.
 












anonymous said:
On a positive note, they didn't issue a liquidity warning within next 12 months in the 10Q, I assume that will come with in the 2nd Quarter.
Click to expand...

If anyone at this dumpster fire even knows how to issue a liquidity warning. They will probably spend the rest of this quarter vacuuming and patching nail holes at the Ardsley space. Gotta get that deposit back to keep RC and LS paychecks clearing,
 








The Pros see investment as a LONG TERM activity for profit. The BioPharmacy industry, with such company as Acorda, generally are considered high value worthy of investment. Look for REBOUND with the Inbrija taking off!!
 












anonymous said:
The Pros see investment as a LONG TERM activity for profit. The BioPharmacy industry, with such company as Acorda, generally are considered high value worthy of investment. Look for REBOUND with the Inbrija taking off!!
Click to expand...

Ha! You are so high value, they froze your ass to keep you from bottoming out.

Quit wrapping yourself in the veil of the industry. ACOR is a shell game of reformulations and stock manipulation hiding behind an actor CEO.
 








Why you are saying this ? My cousin says that many companies want the Inbrija and need to be making the public. There are more who are knowing of Dr Cohen they do not have the Mensa and making the Nobel prize nomination is very good. They will be wanting this Dr too. We are waiting for the reversing to $20 for knowing of the price. This high price will be making the buyers pay more ! Let us be doing this.
 








Top Bottom
Back
Quote